Rabbit Recombinant Monoclonal Clostridium difficile Toxin B antibody. Suitable for WB and reacts with Purified native protein - Clostridium difficile samples. Cited in 2 publications.
pH: 7.2 - 7.4
Preservative: 0.05% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
WB | |
---|---|
Clostridium difficile | Predicted |
Purified native protein - Clostridium difficile | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Purified native protein - Clostridium difficile | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Clostridium difficile | Dilution info - | Notes - |
Toxin B. Precursor of a cytotoxin that targets and disrupts the colonic epithelium, inducing the host inflammatory and innate immune responses and resulting in diarrhea and pseudomembranous colitis (PubMed:20844489, PubMed:24919149). TcdB constitutes the main toxin that mediates the pathology of C.difficile infection, an opportunistic pathogen that colonizes the colon when the normal gut microbiome is disrupted (PubMed:19252482, PubMed:20844489). Compared to TcdA, TcdB is more virulent and more important for inducing the host inflammatory and innate immune responses (PubMed:19252482, PubMed:24919149). This form constitutes the precursor of the toxin: it enters into host cells and mediates autoprocessing to release the active toxin (Glucosyltransferase TcdB) into the host cytosol (PubMed:10768933, PubMed:11152463, PubMed:12941936, PubMed:17334356, PubMed:20498856). Targets colonic epithelia by binding to the frizzled receptors FZD1, FZD2 and FZD7, and enters host cells via clathrin-mediated endocytosis (PubMed:27680706). Frizzled receptors constitute the major host receptors in the colonic epithelium, but other receptors, such as CSPG4 or NECTIN3/PVRL3, have been identified (PubMed:25547119, PubMed:26038560, PubMed:27680706). Binding to carbohydrates and sulfated glycosaminoglycans on host cell surface also contribute to entry into cells (By similarity). Once entered into host cells, acidification in the endosome promotes the membrane insertion of the translocation region and formation of a pore, leading to translocation of the GT44 and peptidase C80 domains across the endosomal membrane (PubMed:11152463, PubMed:12941936, PubMed:24567384). This activates the peptidase C80 domain and autocatalytic processing, releasing the N-terminal part (Glucosyltransferase TcdB), which constitutes the active part of the toxin, in the cytosol (PubMed:17334356, PubMed:27571750). Glucosyltransferase TcdB. Active form of the toxin, which is released into the host cytosol following autoprocessing and inactivates small GTPases (PubMed:16157585, PubMed:17901056, PubMed:24905543, PubMed:24919149, PubMed:7777059, PubMed:8144660). Acts by mediating monoglucosylation of small GTPases of the Rho family (Rac1, RhoA, RhoB, RhoC, RhoG and Cdc42) in host cells at the conserved threonine residue located in the switch I region ('Thr-37/35'), using UDP-alpha-D-glucose as the sugar donor (PubMed:16157585, PubMed:17901056, PubMed:24905543, PubMed:24919149, PubMed:7777059). Monoglucosylation of host small GTPases completely prevents the recognition of the downstream effector, blocking the GTPases in their inactive form, leading to actin cytoskeleton disruption and cell death, resulting in the loss of colonic epithelial barrier function (PubMed:24919149, PubMed:7777059).
Clostridium difficile Toxin B
toxB, tcdB, Toxin B
Rabbit Recombinant Monoclonal Clostridium difficile Toxin B antibody. Suitable for WB and reacts with Purified native protein - Clostridium difficile samples. Cited in 2 publications.
pH: 7.2 - 7.4
Preservative: 0.05% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Clostridium difficile Toxin B also known as CD Toxin B or B protein is a potent toxin produced by the bacterium Clostridium difficile. It is one of the major virulence factors alongside Toxin A. This protein carries significant weight approximately 270 kDa. It is expressed in the intestinal tract when Clostridium difficile colonizes and proliferates often leading to severe gastrointestinal conditions. The presence of toxins including both Toxin A and Toxin B contributes to the pathogenicity of C. diff infection.
This toxin exerts its effects by modifying intracellular signaling pathways disrupting tight junctions and leading to cell apoptosis. Toxin B specifically targets the Rho family of GTPases through glucosylation leading to actin cytoskeleton disorganization and subsequent cell rounding and tissue damage. It functions independently but works in conjunction with Toxin A to enhance virulence. As part of its biological role Toxin B proves essential in the pathogenesis of diseases associated with C. diff infection.
Research shows Toxin B's involvement in the disruption of the actin cytoskeleton pathway. This pathway alteration results from direct modification of small GTP-binding proteins such as RhoA Rac and Cdc42. Toxin B's activity leads to loss of cell structure and increased cell lysis showcasing how it fits into major cellular integrity pathways. Its interaction with these proteins places it alongside other microbial toxins that manipulate host cell signaling.
Toxin B has a strong association with Clostridium difficile infection (CDI) which often manifests as pseudomembranous colitis. CDI presents with symptoms such as severe diarrhea and colonic inflammation. Furthermore Toxin B contributes significantly to the disease severity in comparison to other microbial toxins. While Toxin A also plays a role studies suggest that Toxin B's impact on the intestinal epithelium is more severe marking it as a critical target for therapeutic intervention against CDI.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Blocking and diluting buffer and concentration: 5% NFDM/TBST
Both the recombinant proteins were from Abcam.
Exposure time: lane 1: 3 minutes lane 2: 15 seconds
All lanes: Western blot - Anti-Clostridium difficile Toxin B antibody [EPR23357-19] (ab270452) at 1/1000 dilution
Lane 1: Native Clostridium difficile Toxin A protein (Native Clostridium difficile Toxin A protein ab123999) 10ng
Lane 2: Native Clostridium difficile Toxin B protein (Native Clostridium difficile Toxin B protein ab124001) 10ng
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Predicted band size: 270 kDa
Observed band size: 308 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com